Skip 
Navigation Link

1215 South Walnut Ave.
Demopolis, AL 36732 map map 

Access to Care: 800.239.2901

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Doctors Urged to Speak With Patients About FirearmsStates That Make You Wait to Buy Guns Have Fewer Deaths: StudyHomicides Devastate Black Communities, But Prevention Gets Little FundingBetter Patient Communication Needed After Urgent CareQuality Issues for Both Paper-, Electronic-Based Health RecordsRide-Sharing Services Could Cut Alcohol-Related CrashesLow-Cost Services a Major Player in Unnecessary Health SpendingMedical License Questions Sway Doctors' Mental Health Help'Heat-Not-Burn Cigarettes' Aiming for U.S. MarketFDA Approves Test to Screen Donated Blood for Zika21 Percent of Americans Report Experiencing a Medical ErrorUber Can Help Cut Car Crashes, But Not EverywhereThe Unexpected Faces of the UninsuredHealth Tip: Giving BloodCommunication Program Doesn't Raise Hospital Liability CostsSame Pregnancy Meds Can Cost $200 -- or $11,000Americans More Open About Mental Health Issues, But Stigma Lingers1 in 5 Have Been Hit By a Medical Error, Survey ShowsOpioid Manufacturers to Provide Doctor TrainingPatients' E-Records Still Not Widely AvailableU.S. Gun Injuries Nearing $3 Billion in ER, Hospital CostsState Laws Can Promote Hepatitis C Virus ScreeningTeens Mixed Up With the Law May Fall Through Medicaid CracksState Policies Can Reduce Alcohol-Related MurdersCDC Launches Opioid Campaign in Hard-Hit StatesU.S. Pays a Hefty Price for ObesityBlacks, Elderly Missing From U.S. Cancer Clinical TrialsFood Stamp Benefits May Lower Health Care CostsDrone Sets New Record for Transporting Blood SamplesGun Injuries Add Millions of Dollars to Hospital CostsACP Does Not Support Legalization of Assisted SuicideAAP: Few Doctors Provide Firearm Injury Prevention Info in ER9 of 10 Docs Unprepared to Prescribe MarijuanaThis Mistake Can Cost Athletes' Lives in Cardiac ArrestDrills Assess ER Response to Communicable DiseaseDo Nursing Home Workers Change Gloves Often Enough?Minorities Exposed to Dirtier Air, U.S. Study FindsPhysicians Tweeting About Drugs May Have Conflict of InterestHealth Tip: Overcoming the Obesity EpidemicU.S. Military Surgeons Helped More Than 6,000 Afghan AdultsWhat You Can Do to Help Fight the Opioid EpidemicAre Physicians Obligated to Help on Planes?Median Cost of Cancer Drug Development $648.0 MillionDoes Study Claim a Cure? Beware of Scientific 'Spin'Vaccine Campaign in Poor Countries to Save 20 Million LivesThird Dose of MMR Vaccine Could Help Curb Mumps OutbreaksDocs Should Be Aware of Family Beliefs Regarding NondisclosureIncrease in Medical Exemptions From Immunization in CaliforniaMailed Invitations Increase CRC Screening CompletionMany Americans Getting Medical Care They Don't Need
Questions and AnswersVideosLinksBook Reviews
Related Topics

Health Insurance
Healthcare

Nearly a Third of Drugs Hit by Safety Issues After FDA Approval

HealthDay News
by -- Robert Preidt
Updated: May 10th 2017

new article illustration

WEDNESDAY, May 10, 2017 (HealthDay News) -- Safety problems emerge with nearly one in three prescription drugs after they've been approved by the U.S. Food and Drug Administration, a new study reveals.

Researchers examined data on drugs approved by the FDA between 2001 and 2010, with follow-up through 2017. The investigators found that 32 percent of the drugs had safety issues after approval.

"That is very rarely a drug withdrawal, but more commonly a black-box warning or drug safety communication issued by the FDA to let physicians and patients know that new safety information has been determined," said study leader Dr. Joseph Ross. He is an associate professor of medicine and public health at Yale University.

Of 222 drugs approved by the agency during the study period, three were withdrawn, 61 received boxed warnings and 59 prompted safety communications, the findings showed.

Drugs most likely to have post-approval safety concerns included biologics, psychiatric drugs and medicines approved through the FDA's accelerated approval process.

The report is timely because the FDA is under pressure to accelerate drug approvals, the study authors noted.

"It shows that there is the potential for compromising patient safety when drug evaluation is persistently sped up," Ross said in a university news release.

At the very least, the study should inform the ongoing debate about pre-market drug evaluation, the researchers suggested.

To assess experimental drugs for safety and effectiveness, the FDA relies on pre-market drug testing and clinical trials. Most of the trials involve fewer than 1,000 patients studied over a period of six months or less. This makes it hard to detect safety issues that might surface once more patients use the drug over a longer time period, the researchers explained.

According to study author Dr. Nicholas Downing, from the department of medicine at Brigham and Women's Hospital, in Boston, "The fact that so many new safety risks are being identified after FDA approval indicates that the FDA is taking its responsibility of ensuring the safety of new drugs throughout their lifetime seriously."

However, "these safety risks emerge, on average, four years after approval. This means that many patients are exposed to these medications before the risks become clear," Downing added in a hospital news release.

Some of those risks included serious skin reactions, liver damage, cancer and even death, the Associated Press reported.

The findings were published May 9 in the Journal of the American Medical Association.

More information

There's more about adverse drug reactions from the American Academy of Family Physicians.